Alkeon Capital Management’s Avidity Biosciences RNAM Stock Holding History

Alkeon Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-856,466	Closed	-$12.4M	–	145
2022 Q2	$12.4M	Hold	856,466	–	–	0.03%	120
2022 Q1	$15.8M	Hold	856,466	–	–	0.03%	127
2021 Q4	$20.4M	Sell	856,466 -14,960	-2%	-$357K	0.04%	125
2021 Q3	$21.5M	Hold	871,426	–	–	0.04%	132
2021 Q2	$21.5M	Sell	871,426 -3,574	-0.4%	-$83.1K	0.03%	141
2021 Q1	$19.1M	Hold	875,000	–	–	0.03%	139
2020 Q4	$22.3M	Hold	875,000	–	–	0.04%	134
2020 Q3	$24.6M	Buy	875,000 +100,000	+13%	+$2.89M	0.05%	118
2020 Q2	$21.9M	Buy	+775,000	New	+$22.3M	0.06%	116

Other funds holding RNAM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alkeon Capital Management's RNAM Position: Q3 2022 in Review

Alkeon Capital Management sold out of Avidity Biosciences (RNAM) in Q3 2022, closing a stake of 856,466 shares — an estimated $12.4M sold.

Alkeon Capital Management first reported a position in RNAM in Q2 2020 and held it in 9 quarters. The position peaked at $24.6M in Q3 2020. 127 funds tracked by Wall St. Rank hold RNAM as of Q3 2022.

Alkeon Capital Management reported no remaining Avidity Biosciences position as of Q3 2022 after selling out during the quarter.
Alkeon Capital Management sold 856,466 Avidity Biosciences shares in Q3 2022, an estimated $12.4M.
Alkeon Capital Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 9 quarters.
Alkeon Capital Management's Avidity Biosciences position peaked at $24.6M in Q3 2020.
127 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2022.

Based on Alkeon Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.